Is Rivian a Good Stock a Buy?
Rivian Automotive (RIVN) had an initial IPO of close to…
Sell
19
LPTX Quote, Financials, Valuation and Earnings
Last price:
$0.40
Seasonality move
:
9.9%
Day range:
$0.39 - $0.41
52-week range:
$0.39 - $4.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
8.74x
P/B ratio:
0.31x
Volume:
296.7K
Avg. volume:
388.1K
1-year change:
-84.52%
Market cap:
$14.9M
Revenue:
--
EPS (TTM):
-$1.67
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LPTX
Leap Therapeutics
|
-- | -$0.39 | -- | -91.67% | $3.00 |
|
AIM
AIM ImmunoTech
|
$100K | -$0.09 | -23.08% | -53.85% | $2.75 |
|
ARMP
Armata Pharmaceuticals
|
$1.6M | -$0.35 | -- | -44.93% | $7.00 |
|
CRVO
CervoMed
|
$1.7M | -$0.63 | -- | -52.03% | $15.83 |
|
INO
Inovio Pharmaceuticals
|
$25K | -$0.83 | -75.65% | -43.51% | $7.83 |
|
PLX
Protalix BioTherapeutics
|
$18.7M | -- | 476.31% | -- | $14.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LPTX
Leap Therapeutics
|
$0.39 | $3.00 | $14.9M | -- | $0.00 | 0% | 8.74x |
|
AIM
AIM ImmunoTech
|
$0.14 | $2.75 | $8.9M | -- | $0.00 | 0% | 38.58x |
|
ARMP
Armata Pharmaceuticals
|
$1.84 | $7.00 | $66.6M | -- | $0.00 | 0% | 666.94x |
|
CRVO
CervoMed
|
$10.71 | $15.83 | $93.2M | -- | $0.00 | 0% | 168.72x |
|
INO
Inovio Pharmaceuticals
|
$1.88 | $7.83 | $68.9M | -- | $0.00 | 0% | -- |
|
PLX
Protalix BioTherapeutics
|
$2.60 | $14.50 | $202.9M | 86.67x | $0.00 | 0% | 4.04x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LPTX
Leap Therapeutics
|
-- | -4.296 | -- | -- |
|
AIM
AIM ImmunoTech
|
48.41% | 1.568 | 17.25% | 0.71x |
|
ARMP
Armata Pharmaceuticals
|
-- | 3.254 | -- | -- |
|
CRVO
CervoMed
|
-- | 2.535 | -- | -- |
|
INO
Inovio Pharmaceuticals
|
-- | 2.528 | -- | 2.70x |
|
PLX
Protalix BioTherapeutics
|
-- | 1.969 | -- | 1.47x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LPTX
Leap Therapeutics
|
-- | -$18.4M | -- | -- | -- | -$15.6M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
ARMP
Armata Pharmaceuticals
|
-- | -$10.5M | -- | -- | -- | -$7.9M |
|
CRVO
CervoMed
|
-- | -$7.2M | -- | -- | -- | -$8.1M |
|
INO
Inovio Pharmaceuticals
|
-- | -$20.4M | -114.75% | -119.02% | -16566.39% | -$19.7M |
|
PLX
Protalix BioTherapeutics
|
$14.3M | $7.2M | 6.41% | 8.75% | 40.19% | $3.6M |
Leap Therapeutics vs. Competitors
-
Which has Higher Returns LPTX or AIM?
AIM ImmunoTech has a net margin of -- compared to Leap Therapeutics's net margin of -10571.43%. Leap Therapeutics's return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital LPTXLeap Therapeutics-- -$0.44 -- AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About LPTX or AIM?
Leap Therapeutics has a consensus price target of $3.00, signalling upside risk potential of 669.23%. On the other hand AIM ImmunoTech has an analysts' consensus of $2.75 which suggests that it could grow by 1858.69%. Given that AIM ImmunoTech has higher upside potential than Leap Therapeutics, analysts believe AIM ImmunoTech is more attractive than Leap Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings LPTXLeap Therapeutics0 1 0 AIMAIM ImmunoTech1 0 0 -
Is LPTX or AIM More Risky?
Leap Therapeutics has a beta of 0.348, which suggesting that the stock is 65.246% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.411, suggesting its less volatile than the S&P 500 by 58.887%.
-
Which is a Better Dividend Stock LPTX or AIM?
Leap Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Leap Therapeutics pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LPTX or AIM?
Leap Therapeutics quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Leap Therapeutics's net income of -$18.2M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Leap Therapeutics's price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Leap Therapeutics is 8.74x versus 38.58x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LPTXLeap Therapeutics8.74x -- -- -$18.2M AIMAIM ImmunoTech38.58x -- $35K -$3.7M
-
Which has Higher Returns LPTX or ARMP?
Armata Pharmaceuticals has a net margin of -- compared to Leap Therapeutics's net margin of --. Leap Therapeutics's return on equity of -- beat Armata Pharmaceuticals's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LPTXLeap Therapeutics-- -$0.44 -- ARMPArmata Pharmaceuticals-- -$0.23 -- -
What do Analysts Say About LPTX or ARMP?
Leap Therapeutics has a consensus price target of $3.00, signalling upside risk potential of 669.23%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $7.00 which suggests that it could grow by 280.44%. Given that Leap Therapeutics has higher upside potential than Armata Pharmaceuticals, analysts believe Leap Therapeutics is more attractive than Armata Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings LPTXLeap Therapeutics0 1 0 ARMPArmata Pharmaceuticals0 0 0 -
Is LPTX or ARMP More Risky?
Leap Therapeutics has a beta of 0.348, which suggesting that the stock is 65.246% less volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.887, suggesting its less volatile than the S&P 500 by 11.295%.
-
Which is a Better Dividend Stock LPTX or ARMP?
Leap Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Leap Therapeutics pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LPTX or ARMP?
Leap Therapeutics quarterly revenues are --, which are smaller than Armata Pharmaceuticals quarterly revenues of --. Leap Therapeutics's net income of -$18.2M is lower than Armata Pharmaceuticals's net income of $2.6M. Notably, Leap Therapeutics's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Leap Therapeutics is 8.74x versus 666.94x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LPTXLeap Therapeutics8.74x -- -- -$18.2M ARMPArmata Pharmaceuticals666.94x -- -- $2.6M
-
Which has Higher Returns LPTX or CRVO?
CervoMed has a net margin of -- compared to Leap Therapeutics's net margin of --. Leap Therapeutics's return on equity of -- beat CervoMed's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LPTXLeap Therapeutics-- -$0.44 -- CRVOCervoMed-- -$0.80 -- -
What do Analysts Say About LPTX or CRVO?
Leap Therapeutics has a consensus price target of $3.00, signalling upside risk potential of 669.23%. On the other hand CervoMed has an analysts' consensus of $15.83 which suggests that it could grow by 47.84%. Given that Leap Therapeutics has higher upside potential than CervoMed, analysts believe Leap Therapeutics is more attractive than CervoMed.
Company Buy Ratings Hold Ratings Sell Ratings LPTXLeap Therapeutics0 1 0 CRVOCervoMed5 1 0 -
Is LPTX or CRVO More Risky?
Leap Therapeutics has a beta of 0.348, which suggesting that the stock is 65.246% less volatile than S&P 500. In comparison CervoMed has a beta of 1.837, suggesting its more volatile than the S&P 500 by 83.67%.
-
Which is a Better Dividend Stock LPTX or CRVO?
Leap Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CervoMed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Leap Therapeutics pays -- of its earnings as a dividend. CervoMed pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LPTX or CRVO?
Leap Therapeutics quarterly revenues are --, which are smaller than CervoMed quarterly revenues of --. Leap Therapeutics's net income of -$18.2M is lower than CervoMed's net income of -$6.7M. Notably, Leap Therapeutics's price-to-earnings ratio is -- while CervoMed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Leap Therapeutics is 8.74x versus 168.72x for CervoMed. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LPTXLeap Therapeutics8.74x -- -- -$18.2M CRVOCervoMed168.72x -- -- -$6.7M
-
Which has Higher Returns LPTX or INO?
Inovio Pharmaceuticals has a net margin of -- compared to Leap Therapeutics's net margin of -16566.39%. Leap Therapeutics's return on equity of -- beat Inovio Pharmaceuticals's return on equity of -119.02%.
Company Gross Margin Earnings Per Share Invested Capital LPTXLeap Therapeutics-- -$0.44 -- INOInovio Pharmaceuticals-- -$0.60 $68.5M -
What do Analysts Say About LPTX or INO?
Leap Therapeutics has a consensus price target of $3.00, signalling upside risk potential of 669.23%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $7.83 which suggests that it could grow by 316.67%. Given that Leap Therapeutics has higher upside potential than Inovio Pharmaceuticals, analysts believe Leap Therapeutics is more attractive than Inovio Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings LPTXLeap Therapeutics0 1 0 INOInovio Pharmaceuticals2 3 0 -
Is LPTX or INO More Risky?
Leap Therapeutics has a beta of 0.348, which suggesting that the stock is 65.246% less volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 0.917, suggesting its less volatile than the S&P 500 by 8.256%.
-
Which is a Better Dividend Stock LPTX or INO?
Leap Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Leap Therapeutics pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LPTX or INO?
Leap Therapeutics quarterly revenues are --, which are smaller than Inovio Pharmaceuticals quarterly revenues of $117K. Leap Therapeutics's net income of -$18.2M is higher than Inovio Pharmaceuticals's net income of -$19.4M. Notably, Leap Therapeutics's price-to-earnings ratio is -- while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Leap Therapeutics is 8.74x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LPTXLeap Therapeutics8.74x -- -- -$18.2M INOInovio Pharmaceuticals-- -- $117K -$19.4M
-
Which has Higher Returns LPTX or PLX?
Protalix BioTherapeutics has a net margin of -- compared to Leap Therapeutics's net margin of 35.65%. Leap Therapeutics's return on equity of -- beat Protalix BioTherapeutics's return on equity of 8.75%.
Company Gross Margin Earnings Per Share Invested Capital LPTXLeap Therapeutics-- -$0.44 -- PLXProtalix BioTherapeutics78.67% $0.09 $43.2M -
What do Analysts Say About LPTX or PLX?
Leap Therapeutics has a consensus price target of $3.00, signalling upside risk potential of 669.23%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 457.69%. Given that Leap Therapeutics has higher upside potential than Protalix BioTherapeutics, analysts believe Leap Therapeutics is more attractive than Protalix BioTherapeutics.
Company Buy Ratings Hold Ratings Sell Ratings LPTXLeap Therapeutics0 1 0 PLXProtalix BioTherapeutics0 0 0 -
Is LPTX or PLX More Risky?
Leap Therapeutics has a beta of 0.348, which suggesting that the stock is 65.246% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.611%.
-
Which is a Better Dividend Stock LPTX or PLX?
Leap Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Leap Therapeutics pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LPTX or PLX?
Leap Therapeutics quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. Leap Therapeutics's net income of -$18.2M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Leap Therapeutics's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 86.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Leap Therapeutics is 8.74x versus 4.04x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LPTXLeap Therapeutics8.74x -- -- -$18.2M PLXProtalix BioTherapeutics4.04x 86.67x $18.2M $6.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Chevron Acquire Hess?
Long-time Buffett favorite in the energy sector Chevron (NYSE:CVX) is…
Why Did Progressive Stock Go Down?
Shares of insurance giant Progressive (NYSE:PGR) have fallen considerably over…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
47
RGC alert for Mar 25
Regencell Bioscience Holdings [RGC] is up 4.9% over the past day.
Buy
54
AZEK alert for Mar 25
The AZEK [AZEK] is up 1.01% over the past day.
Sell
36
MPTI alert for Mar 25
M-Tron Industries [MPTI] is up 7.48% over the past day.
